Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)-Reference-Cited by-同舟云学术

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS)

Published:2020-06 Issue:6 Volume:203 Page:1163-1171
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Kaplan Steven A.¹,Herschorn Sender²,McVary Kevin T.³,Staskin David⁴,Chapple Christopher⁵,Foley Steve⁶,Cambronero Santos Javier⁷,Kristy Rita M.⁸,Choudhury Nurul⁹,Hairston John⁸,Schermer Carol R.⁸

Affiliation:

1. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, New York

2. Department of Surgery/Urology, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

3. Department of Urology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois

4. Division of Urology, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, Massachusetts

5. Department of Urology, Royal Hallamshire Hospital, Sheffield, UK

6. Department of Urology, Royal Berkshire Hospital, Reading, UK

7. Department of Urology, Infanta Leonor Hospital, Madrid, Spain

8. Astellas Pharma Global Development Inc., Northbrook, Illinois

9. Astellas Pharma Europe Ltd., Chertsey, UK

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comination pharmacotherapy of lower urinary tract symptoms;Urologie pro praxi;2024-03-15

2. Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023;Neurourology and Urodynamics;2024-03-13

3. Safety and efficacy of an α₁‐blocker plus mirabegron compared with an α₁‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta‐analysis;Neurourology and Urodynamics;2024-01-30

4. Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials;Urologia Internationalis;2024

5. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia;Expert Opinion on Drug Safety;2023-12-02